Zhenya Lindgardt Sells 20,139 Shares of Sera Prognostics (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 20,139 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $2.00, for a total value of $40,278.00. Following the completion of the sale, the chief executive officer owned 844,870 shares in the company, valued at $1,689,740. This represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Stock Up 2.5%

Shares of NASDAQ:SERA opened at $2.05 on Friday. The firm has a market capitalization of $80.87 million, a PE ratio of -3.06 and a beta of 0.98. The company has a 50-day moving average price of $2.05 and a two-hundred day moving average price of $2.02. Sera Prognostics, Inc. has a twelve month low of $1.56 and a twelve month high of $3.95.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.03). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.07 million. Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. Analysts anticipate that Sera Prognostics, Inc. will post -0.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SERA. Weiss Ratings lowered Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Craig Hallum initiated coverage on Sera Prognostics in a research note on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Institutional Trading of Sera Prognostics

A number of hedge funds and other institutional investors have recently bought and sold shares of SERA. Arkadios Wealth Advisors purchased a new stake in Sera Prognostics in the 1st quarter worth approximately $25,000. Lido Advisors LLC purchased a new position in shares of Sera Prognostics during the 3rd quarter valued at $68,000. Cetera Investment Advisers purchased a new position in shares of Sera Prognostics during the 4th quarter valued at $74,000. Qube Research & Technologies Ltd purchased a new position in shares of Sera Prognostics during the 2nd quarter valued at $92,000. Finally, Two Sigma Investments LP bought a new position in shares of Sera Prognostics in the third quarter worth $97,000. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.